PURPOSE: This phase II study was undertaken to determine the efficacy of adding infusional @entity1487 (FU) to the chemotherapy doublet of @entity136 and @entity900 in @entity1 with advanced @entity788 . @entity1 AND METHODS: The eligibility criteria included histologically or cytologically confirmed @entity420 that was either unresectable or metastatic. No prior @entity136 therapy was allowed. @entity1 received a combination of @entity136 1000 mg/m2 intravenously (IV) on days 1, 8, and 15; @entity900 50 mg/m2 IV on days 1 and 15; and FU 175 mg/m2/d from days 1 to 15 by continuous IV infusion. Cycles were repeated every 28 days. Objective @entity5 response and @entity137 were evaluated according to the World Health Organization criteria. RESULTS: A total of 47 @entity1 (median age, 57 years; males, 59%) were enrolled. Sixteen @entity1 had locally advanced (LA) disease, and 31 @entity1 had @entity3 . A total of 183 cycles of chemotherapy were administered. In @entity1 with @entity3 (n = 31), the probability of survival at 6 and 12 months was 66% and 34%, respectively. Objective partial response or stable disease was observed in 26% (90% confidence interval [CI], 0.14 to 0.41) and 61% (90% CI, 0.45 to 0.74) of @entity1 , respectively. In @entity1 with @entity1442 (n = 16), there were three partial responses (19%; 90 CI, 0.07 to 0.39). One @entity1 in this group was successfully resected after FU-based radiotherapy. The most common grade 3 to 4 @entity137 were @entity1398 (60%), @entity882 (42%), and @entity417 (26%). Thirteen @entity1 were hospitalized for treatment-related complications. CONCLUSION: The combination of @entity136 , @entity900 , and infusional FU has significant activity in @entity1 with advanced @entity788 .

Phase II study of @entity136 , XXXX , and infusional @entity1487 in advanced @entity788 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma of the pancreas'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['LA disease'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['fluorouracil']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
